AlphaQuest’s TG Therapeutics TGTX Stock Holding History

AlphaQuest’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,221	Closed	-$96K	–	1875
2025 Q4	$96K	Sell	3,221 -1,052	-25%	-$34.4K	0.01%	1759
2025 Q3	$154K	Buy	4,273 +4,138	+3,065%	+$136K	0.01%	1533
2025 Q2	$4.86K	Buy	+135	New	+$5.03K	﹤0.01%	1889
2024 Q4	–	Sell	-10,529	Closed	-$246K	–	2012
2024 Q3	$246K	Buy	+10,529	New	+$230K	0.02%	980
2024 Q2	–	Sell	-1	Closed	-$15	–	1892
2024 Q1	$15	Sell	1 -1,410	-100%	-$22.5K	﹤0.01%	1626
2023 Q4	$24.1K	Buy	+1,411	New	+$16.4K	0.01%	950

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

AlphaQuest's TGTX Position: Q1 2026 in Review

AlphaQuest sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 3,221 shares — an estimated $96K sold.

AlphaQuest first reported a position in TGTX in Q4 2023 and held it in 6 quarters. The position peaked at $246K in Q3 2024. 365 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

AlphaQuest reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 3,221 TG Therapeutics shares in Q1 2026, an estimated $96K.
AlphaQuest first reported a position in TG Therapeutics in Q4 2023 and held it in 6 quarters.
AlphaQuest's TG Therapeutics position peaked at $246K in Q3 2024.
365 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.